10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2022 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 8, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash flows from operating activities: | |||
| Cash receipts from customers | $ 313,662 | 284,219 | 264,327 |
| Cash paid for inventory and prescriptions dispensed by retail network pharmacies | (189,766) | (165,783) | (158,636) |
| Insurance benefits paid | (69,728) | (63,598) | (55,124) |
| Cash paid to other suppliers and employees | (32,662) | (31,652) | (29,763) |
| Interest and investment income received | 1,026 | 743 | 894 |
| Interest paid | (2,239) | (2,469) | (2,904) |
| Income taxes paid | (4,116) | (3,195) | (2,929) |
| Net cash provided by operating activities | 16,177 | 18,265 | 15,865 |
| Cash flows from investing activities: | |||
| Proceeds from sales and maturities of investments | 6,729 | 7,246 | 6,467 |
| Purchases of investments | (7,746) | (9,963) | (9,639) |
| Purchases of property and equipment | (2,727) | (2,520) | (2,437) |
| Proceeds from sale-leaseback transactions | 0 | 0 | 101 |
| Acquisitions (net of cash acquired) | (139) | (146) | (866) |
| Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $2,854, $0 and $9) | (1,249) | 0 | 840 |
| Other | 85 | 122 | 0 |
| Net cash used in investing activities | (5,047) | (5,261) | (5,534) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of long-term debt | 0 | 987 | 9,958 |
| Repayments of long-term debt | (4,211) | (10,254) | (15,631) |
| Derivative settlements | 0 | 0 | (7) |
| Repurchase of common stock | (3,500) | 0 | 0 |
| Dividends paid | (2,907) | (2,625) | (2,624) |
| Proceeds from exercise of stock options | 551 | 549 | 264 |
| Payments for taxes related to net share settlement of equity awards | (370) | (168) | (88) |
| Other | (79) | 155 | 432 |
| Net cash used in financing activities | (10,516) | (11,356) | (7,696) |
| Net increase in cash, cash equivalents and restricted cash | 614 | 1,648 | 2,635 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 12,691 | 11,043 | |
| Cash, cash equivalents and restricted cash at the end of the period | 13,305 | 12,691 | 11,043 |
| Reconciliation of net income to net cash provided by operating activities: | |||
| Net income | 4,165 | 7,898 | 7,192 |
| Adjustments required to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 4,247 | 4,512 | 4,441 |
| Loss on assets held for sale | 2,533 | 0 | 0 |
| Store impairments | 0 | 1,358 | 0 |
| Goodwill impairment | 0 | 431 | 0 |
| Stock-based compensation | 447 | 484 | 400 |
| Gain on sale of subsidiaries | (475) | 0 | (269) |
| Loss on early extinguishment of debt | 0 | 452 | 1,440 |
| Deferred income taxes | (2,075) | (428) | (570) |
| Other noncash items | 332 | (390) | 72 |
| Change in operating assets and liabilities, net of effects from acquisitions: | |||
| Accounts receivable, net | (2,971) | (2,703) | (1,510) |
| Inventories | (1,435) | 735 | (973) |
| Other assets | (566) | (3) | 364 |
| Accounts payable and pharmacy claims and discounts payable | 4,260 | 2,898 | 2,769 |
| Health care costs payable and other insurance liabilities | 1,247 | 169 | (231) |
| Other liabilities | 6,468 | 2,852 | 2,740 |
| Net cash provided by operating activities | 16,177 | 18,265 | 15,865 |
| External Links | |
| CVS HEALTH CORP (CVS) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |